Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Septerna (Nasdaq: SEPN) announced that CEO and co‑founder Jeffrey Finer, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast of the presentation will be available in the company's investor relations section at www.septerna.com, and the webcast will be archived for at least 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, SEPN gained 1.22%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: ANAB -0.16%, KROS +1.75%, SVRA -1.38%, TERN -2.65%, TYRA +1.82%. With SEPN down 3.5% pre‑news and no peers in momentum scanners, trading appeared stock-specific rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conference | Neutral | -1.9% | Announced participation in Evercore healthcare conference with webcast and 30-day archive. |
| Nov 10 | Earnings and pipeline | Positive | -2.2% | Reported profitable Q3 2025 and pipeline progress including SEP-479 and SEP-631. |
| Nov 03 | Investor conferences | Neutral | -2.7% | Planned participation in November investor events with live webcasts and archives. |
| Sep 29 | Board appointment | Positive | +4.0% | Added experienced biotech leader to Board and chair of new R&D Committee. |
| Aug 27 | Investor conferences | Neutral | -0.6% | Announced September conference presentations with webcasts and 30-day replay access. |
Recent conference participation headlines have typically coincided with modest negative or muted price reactions, while a positive management/board update saw a stronger upside move.
Over the last several months, Septerna has mainly reported investor conference participation and corporate developments, alongside a profitable Q3 2025. Earnings on Nov 10, 2025 highlighted collaboration-driven revenue and net income but the stock fell 2.22%. Multiple conference participation announcements on Aug 27, Nov 3, and Nov 25, 2025 were followed by small declines. In contrast, the appointment of Keith Gottesdiener to the Board on Sep 29, 2025 coincided with a 4.01% gain, suggesting governance and leadership updates have drawn a more positive market response than conference notices.
Market Pulse Summary
This announcement highlights Septerna’s upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, with a webcast available and archived for at least 30 days. In recent months, the company has focused on investor outreach and reported profitable Q3 2025 results, while the stock traded above its 200-day MA. Investors may watch for any new clinical, partnership, or financial details disclosed during the conference webcast.
Key Terms
g protein-coupled receptor (gpcr) medical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT in San Francisco.
A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform™ is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
FAQ
When will Septerna (SEPN) present at the J.P. Morgan Healthcare Conference?
How can investors watch Septerna's (SEPN) presentation on January 13, 2026?
How long will Septerna's (SEPN) J.P. Morgan presentation be available online?
Who is presenting for Septerna (SEPN) at the 44th Annual J.P. Morgan Healthcare Conference?
Where will Septerna's (SEPN) J.P. Morgan presentation take place?
